Current Report Filing (8-k)
April 21 2023 - 3:31PM
Edgar (US Regulatory)
0001614067
false
0001614067
2023-04-19
2023-04-19
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
8-K
CURRENT
REPORT
Pursuant
to Section 13 or 15(d) of the
Securities
Exchange Act of 1934
Date
of Report (Date of earliest event reported)
April
19, 2023
Aridis
Pharmaceuticals, Inc.
(Exact
name of registrant as specified in its charter)
| Delaware |
|
001-38630 |
|
47-2641188 |
(State
or other jurisdiction of
incorporation) |
|
(Commission
File
Number) |
|
(I.
R. S. Employer
Identification
No.) |
983
University Avenue, Bldg. B
Los
Gatos, California 95032
(Address
of principal executive offices, including ZIP code)
(408)
385-1742
(Registrant’s
telephone number, including area code)
(Former
name or former address, if changed since last report)
Securities
registered pursuant to Section 12(b) of the Act:
| Title
of each class: |
|
Trading
Symbol(s) |
|
Name
of each exchange on which registered: |
| Common
Stock |
|
ARDS |
|
Nasdaq
Capital Market |
Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under
any of the following provisions:
| ☐
|
Written
communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| |
|
| ☐ |
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| |
|
| ☐ |
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| |
|
| ☐
|
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Indicate
by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405
of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging
growth company ☒
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.
| Item
3.01 |
Notice
of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing. |
On
April 19, 2023, Aridis Pharmaceuticals, Inc. (the “Company”) received written notice (the “Notice”) from
the Nasdaq Stock Market, LLC (“Nasdaq”) indicating that Nasdaq had not received the Company’s Form 10-K for
the year ended December 31, 2022 and this serves as an additional basis for delisting the Company’s securities from The Nasdaq
Capital Market. Since the Company already has a hearing date of May 4, 2023 before the Hearings Panel for its failure to comply with
the $35 million minimum market value of listed securities requirement under Listing Rule 5550(b)(2), the Company has until April 26,
2023 to request a stay of the suspension of the Company’s securities pending a Hearings Panel decision. The Company plans to request
a stay of the suspension pending the Hearings Panel decision.
On
April 20, 2023, the Company received written notice from Nasdaq that due to the resignation of Craig Gibbs, Ph.D. from the Company’s
board and audit committee on March 27, 2023, the Company no longer complies with Nasdaq’s independent director and audit committee
requirements as set forth in Listing Rule 5605. Pursuant to Nasdaq’s cure period, the Company is required to regain compliance
by the earlier of the Company’s next annual shareholders’ meeting or March 27, 2024 or if the next annual shareholders’
meeting is held before September 25, 2023, then the Company must evidence compliance no later than September 25, 2023.
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized.
| Date:
April 21, 2023 |
ARIDIS
PHARMACEUTICALS, INC. |
| |
|
| |
/s/
Vu Truong |
| |
Vu
Truong |
| |
Chief
Executive Officer |
Aridis Pharmaceuticals (NASDAQ:ARDS)
Historical Stock Chart
From Jun 2024 to Jul 2024
Aridis Pharmaceuticals (NASDAQ:ARDS)
Historical Stock Chart
From Jul 2023 to Jul 2024
